MeSH term
Frequency | Condition_Probility | Adolescent | 365 | 2.0 |
Adult | 701 | 1.0 |
Blood Glucose/*metabolism | 105 | 40.0 |
Child | 213 | 1.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology | 26 | 68.0 |
English Abstract | 168 | 1.0 |
Exercise/*physiology | 2 | 0.0 |
Female | 885 | 1.0 |
Hemoglobin A, Glycosylated/analysis | 323 | 74.0 |
Humans | 1208 | 0.0 |
Hydrocortisone/blood | 7 | 1.0 |
Male | 822 | 1.0 |
Aged | 292 | 0.0 |
Comparative Study | 315 | 1.0 |
Diabetes Mellitus, Type 2/*blood/diagnosis | 2 | 66.0 |
Logistic Models | 8 | 1.0 |
Middle Aged | 554 | 1.0 |
Predictive Value of Tests | 12 | 0.0 |
Probability | 3 | 0.0 |
Prognosis | 24 | 0.0 |
Prospective Studies | 87 | 2.0 |
Research Support, Non-U.S. Gov't | 451 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Severity of Illness Index | 7 | 0.0 |
alpha-Macroglobulins/*analysis | 3 | 13.0 |
African Continental Ancestry Group | 5 | 1.0 |
Blood Glucose/analysis | 213 | 33.0 |
Blood Pressure/physiology | 7 | 4.0 |
*Diabetes Complications | 11 | 20.0 |
Retrospective Studies | 24 | 0.0 |
Risk Factors | 86 | 1.0 |
South Africa/epidemiology | 2 | 3.0 |
Time Factors | 123 | 1.0 |
Diabetes Mellitus, Type 2/*drug therapy | 17 | 70.0 |
Double-Blind Method | 48 | 2.0 |
Gliclazide/*therapeutic use | 6 | 100.0 |
Glyburide/*therapeutic use | 9 | 90.0 |
Hypoglycemic Agents/*therapeutic use | 21 | 36.0 |
Oxidative Stress/*drug effects | 2 | 5.0 |
Blood Pressure/drug effects | 9 | 1.0 |
Hypertension/complications/drug therapy | 3 | 21.0 |
Kidney/physiopathology | 3 | 5.0 |
Proteinuria | 3 | 7.0 |
Diabetes Mellitus, Type 2/*complications | 8 | 21.0 |
Blood Pressure | 47 | 7.0 |
Case-Control Studies | 16 | 0.0 |
Cohort Studies | 26 | 1.0 |
Diabetes Mellitus, Type 1/*complications/physiopathology | 5 | 62.0 |
Glomerular Filtration Rate | 9 | 7.0 |
Kidney/*pathology | 4 | 7.0 |
Patient Selection | 2 | 1.0 |
Reference Values | 110 | 2.0 |
Age of Onset | 13 | 1.0 |
European Continental Ancestry Group | 6 | 0.0 |
Incidence | 18 | 1.0 |
Pennsylvania/epidemiology | 2 | 14.0 |
Research Support, U.S. Gov't, P.H.S. | 113 | 0.0 |
Anxiety | 4 | 28.0 |
*Awareness | 2 | 22.0 |
Blood Glucose/analysis/*physiology | 2 | 100.0 |
Blood Glucose Self-Monitoring | 17 | 100.0 |
Follow-Up Studies | 104 | 2.0 |
*Patient Education | 22 | 59.0 |
Psychological Tests | 3 | 7.0 |
Anthropometry | 8 | 3.0 |
Energy Metabolism | 2 | 1.0 |
Long-Term Care | 3 | 5.0 |
Statistics, Nonparametric | 9 | 0.0 |
Thailand | 2 | 1.0 |
Treatment Outcome | 10 | 0.0 |
Aged, 80 and over | 41 | 0.0 |
Diabetes Complications | 24 | 16.0 |
*Population Surveillance | 2 | 5.0 |
Prevalence | 29 | 2.0 |
*Quality of Life | 5 | 5.0 |
Questionnaires | 36 | 6.0 |
England/epidemiology | 3 | 5.0 |
Blood Glucose/*analysis | 74 | 59.0 |
Cross-Over Studies | 6 | 0.0 |
Diabetes Mellitus, Type 1/blood/*drug therapy/psychology | 4 | 100.0 |
Diabetic Diet | 22 | 68.0 |
Energy Intake | 7 | 3.0 |
Insulin/*administration & dosage/therapeutic use | 12 | 75.0 |
Medical Records | 2 | 2.0 |
Quality of Life | 4 | 2.0 |
Self Care | 10 | 58.0 |
Stress, Psychological | 2 | 7.0 |
India/epidemiology | 4 | 4.0 |
Sex Distribution | 2 | 0.0 |
Diabetes Mellitus/*blood/physiopathology | 2 | 25.0 |
Fibrinogen/*metabolism | 3 | 4.0 |
Hyperglycemia/*blood | 6 | 40.0 |
Biological Markers/blood | 23 | 1.0 |
Disease Progression | 14 | 0.0 |
Fasting | 41 | 13.0 |
Fructosamine/blood | 5 | 62.0 |
Hemoglobin A, Glycosylated/*analysis | 201 | 91.0 |
Serum Albumin/analysis | 5 | 2.0 |
Chromatography, Ion Exchange | 15 | 4.0 |
Animals | 20 | 0.0 |
Base Composition | 2 | 0.0 |
Child, Preschool | 81 | 0.0 |
Mice | 3 | 0.0 |
Phenotype | 7 | 0.0 |
Syndrome | 2 | 0.0 |
Drug Administration Schedule | 31 | 3.0 |
Drug Therapy, Combination | 34 | 2.0 |
Insulin/*therapeutic use | 51 | 62.0 |
Sulfonylurea Compounds/therapeutic use | 6 | 50.0 |
Treatment Failure | 4 | 1.0 |
Age Factors | 48 | 1.0 |
Body Mass Index | 37 | 3.0 |
Parity | 3 | 2.0 |
Pregnancy | 63 | 1.0 |
Chromatography, High Pressure Liquid | 18 | 1.0 |
Hemoglobins, Abnormal/*analysis | 4 | 20.0 |
Isoelectric Focusing | 4 | 0.0 |
Diabetes Mellitus, Type 2/*blood/physiopathology | 4 | 25.0 |
Diabetic Angiopathies/*blood | 10 | 47.0 |
Diabetic Nephropathies/blood | 5 | 41.0 |
Diabetic Retinopathy/blood | 9 | 47.0 |
Erythrocytes/enzymology | 3 | 0.0 |
Glutathione Peroxidase/*blood | 2 | 11.0 |
Lipid Peroxides/blood | 3 | 12.0 |
Lipoproteins, HDL Cholesterol/blood | 34 | 4.0 |
Lipoproteins, LDL Cholesterol/blood | 19 | 3.0 |
Superoxide Dismutase/*blood | 2 | 7.0 |
Thiobarbituric Acid Reactive Substances/analysis | 2 | 9.0 |
Triglycerides/blood | 94 | 6.0 |
Confidence Intervals | 3 | 0.0 |
Demography | 7 | 6.0 |
Diabetic Neuropathies/epidemiology | 2 | 100.0 |
Diabetic Retinopathy/epidemiology | 9 | 90.0 |
Morbidity | 4 | 6.0 |
Poverty | 2 | 9.0 |
Proteinuria/epidemiology | 2 | 66.0 |
*Socioeconomic Factors | 3 | 60.0 |
Leg/*blood supply | 2 | 6.0 |
Smoking/adverse effects | 3 | 1.0 |
*Glucose Tolerance Test | 19 | 33.0 |
Insulin Resistance | 9 | 5.0 |
Lipids/blood | 27 | 4.0 |
Hemoglobin E/*genetics | 2 | 40.0 |
Infant, Newborn | 34 | 0.0 |
Pedigree | 2 | 0.0 |
Fibrinogen/analysis | 6 | 3.0 |
Blood Glucose/metabolism | 159 | 22.0 |
Glucose Clamp Technique | 13 | 12.0 |
Insulin/administration & dosage/therapeutic use | 10 | 76.0 |
*Insulin Resistance | 11 | 5.0 |
Biological Markers/*blood | 7 | 4.0 |
Diabetes Mellitus, Type 1/blood/physiopathology | 2 | 66.0 |
Diabetes Mellitus, Type 2/blood/physiopathology | 2 | 40.0 |
Fluorescein Angiography | 5 | 4.0 |
Base Sequence | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Cholesterol/blood | 87 | 7.0 |
Placebos | 5 | 2.0 |
Postprandial Period | 5 | 5.0 |
Cross-Sectional Studies | 27 | 2.0 |
Diabetes Mellitus, Type 2/*drug therapy/*physiopathology/psychology | 2 | 100.0 |
Motivation | 2 | 10.0 |
Norway | 6 | 5.0 |
Primary Health Care | 2 | 14.0 |
Antigens, CD/analysis | 2 | 0.0 |
Platelet Aggregation/drug effects | 4 | 1.0 |
Analysis of Variance | 40 | 1.0 |
C-Peptide/*urine | 3 | 75.0 |
Creatinine/blood | 13 | 4.0 |
Islets of Langerhans/*physiopathology | 9 | 56.0 |
Diabetes Mellitus/*diagnosis | 9 | 100.0 |
Fetal Hemoglobin/*metabolism | 2 | 33.0 |
Hemoglobin A/*metabolism | 7 | 46.0 |
Hemoglobin A, Glycosylated | 2 | 66.0 |
Insulin/metabolism | 2 | 1.0 |
*Body Mass Index | 2 | 2.0 |
C-Peptide/*blood | 13 | 36.0 |
Diabetes Mellitus, Type 2/blood/*complications | 8 | 40.0 |
Diabetic Angiopathies/epidemiology | 6 | 75.0 |
Diabetic Nephropathies/epidemiology | 2 | 100.0 |
Germany/epidemiology | 2 | 1.0 |
Randomized Controlled Trials | 5 | 1.0 |
Albuminuria/*epidemiology | 5 | 71.0 |
Diabetes Mellitus, Type 1/*physiopathology/urine | 3 | 75.0 |
Diabetic Nephropathies/*epidemiology | 2 | 50.0 |
Multivariate Analysis | 17 | 1.0 |
Smoking | 17 | 4.0 |
Diabetes Mellitus, Type 1/*complications | 13 | 48.0 |
Forecasting | 2 | 0.0 |
Hyperglycemia/complications | 3 | 33.0 |
Hypertension/complications | 7 | 11.0 |
Diabetes Mellitus/blood | 31 | 45.0 |
Blood Glucose/drug effects/metabolism | 6 | 25.0 |
Glyburide/therapeutic use | 7 | 77.0 |
Hemoglobin A, Glycosylated/metabolism | 98 | 66.0 |
Hypoglycemic Agents/therapeutic use | 15 | 34.0 |
Diabetes Mellitus, Type 2/metabolism/*physiopathology | 2 | 50.0 |
Longitudinal Studies | 33 | 3.0 |
Obesity/*physiopathology | 2 | 3.0 |
Radioimmunoassay | 15 | 0.0 |
Calcium/*urine | 2 | 6.0 |
Diabetes Mellitus, Type 1/*metabolism | 24 | 42.0 |
Sex Characteristics | 18 | 3.0 |
Diabetes Mellitus, Type 2/*drug therapy/metabolism | 2 | 28.0 |
Regression Analysis | 57 | 3.0 |
Sex Factors | 34 | 2.0 |
Capillaries | 3 | 5.0 |
Diabetes Mellitus/*blood | 53 | 56.0 |
Chylomicrons/*blood | 2 | 6.0 |
Diabetes Mellitus, Type 2/*blood | 40 | 34.0 |
Oxidation-Reduction | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Glucose/*metabolism | 4 | 2.0 |
Biological Markers | 4 | 0.0 |
Coronary Disease/*blood | 2 | 3.0 |
Diabetes Mellitus, Type 1/*blood | 90 | 63.0 |
Insulin Resistance/physiology | 3 | 6.0 |
Particle Size | 2 | 0.0 |
Diabetes Mellitus, Type 1/*physiopathology | 25 | 47.0 |
Insulin-Like Growth Factor I/*metabolism | 5 | 3.0 |
Albuminuria/*etiology | 2 | 50.0 |
Diabetic Angiopathies/etiology | 4 | 66.0 |
Histocompatibility Testing | 3 | 0.0 |
*Dietary Supplements | 2 | 3.0 |
Electrophysiology | 4 | 0.0 |
Motor Neurons/physiology | 7 | 14.0 |
Neural Conduction/*drug effects | 2 | 33.0 |
Blood Glucose Self-Monitoring/statistics & numerical data | 2 | 100.0 |
Diabetes Mellitus, Type 1/blood/*complications | 6 | 75.0 |
Hypoglycemia/*etiology | 2 | 28.0 |
Insulin/blood | 28 | 4.0 |
Pregnancy Trimester, First | 8 | 2.0 |
Pregnancy Trimester, Second | 5 | 2.0 |
Deoxyglucose/blood | 2 | 100.0 |
Adaptation, Psychological | 6 | 12.0 |
Diabetes Mellitus, Type 1/blood/*psychology/rehabilitation | 2 | 100.0 |
Germany | 6 | 1.0 |
*Internal-External Control | 4 | 28.0 |
*Sick Role | 3 | 21.0 |
Acute Disease | 3 | 0.0 |
Chi-Square Distribution | 7 | 0.0 |
Indians, North American | 5 | 15.0 |
Odds Ratio | 7 | 0.0 |
C-Peptide/blood | 55 | 32.0 |
Diabetes Mellitus, Type 1/*drug therapy | 23 | 79.0 |
Enzyme Inhibitors/adverse effects/*therapeutic use | 2 | 25.0 |
Hypoglycemic Agents/adverse effects/*therapeutic use | 5 | 83.0 |
Acarbose | 9 | 81.0 |
Trisaccharides/adverse effects/*therapeutic use | 2 | 100.0 |
India | 5 | 1.0 |
Proteinuria/*complications | 2 | 50.0 |
*Fear | 2 | 33.0 |
Hypoglycemia/etiology/*psychology | 3 | 100.0 |
*Mother-Child Relations | 2 | 28.0 |
Chronic Disease | 10 | 0.0 |
Boronic Acids | 4 | 80.0 |
*African Continental Ancestry Group | 6 | 5.0 |
*European Continental Ancestry Group | 5 | 5.0 |
Systole | 6 | 7.0 |
Body Weight/drug effects | 8 | 4.0 |
Dose-Response Relationship, Drug | 16 | 0.0 |
Glucose Tolerance Test | 62 | 15.0 |
Diabetes Mellitus, Type 1/*blood/genetics | 2 | 66.0 |
Acetylglucosaminidase/*blood | 3 | 60.0 |
Biological Markers/blood/urine | 3 | 6.0 |
Blood Proteins/analysis | 3 | 1.0 |
Deoxyglucose/*blood | 2 | 66.0 |
*Birth Weight | 9 | 23.0 |
Pregnancy Outcome | 3 | 1.0 |
Pregnancy in Diabetics/blood/*physiopathology | 3 | 100.0 |
Hypertension/epidemiology | 3 | 7.0 |
Korea/epidemiology | 2 | 3.0 |
Romania | 2 | 11.0 |
Diabetes Mellitus, Type 2/drug therapy/*metabolism | 2 | 40.0 |
Enalapril/*pharmacology | 2 | 6.0 |
Hypoglycemic Agents/administration & dosage/*therapeutic use | 4 | 44.0 |
Insulin/administration & dosage/*therapeutic use | 13 | 81.0 |
Lipoproteins/blood | 9 | 2.0 |
Single-Blind Method | 4 | 1.0 |
Hyperglycemia/prevention & control | 3 | 75.0 |
Hypoglycemic Agents/administration & dosage/therapeutic use | 2 | 50.0 |
Postpartum Period/blood | 2 | 10.0 |
Diabetes Mellitus, Type 2/*physiopathology | 8 | 25.0 |
Heart Rate/drug effects | 7 | 2.0 |
Hematocrit | 4 | 1.0 |
Hemoglobin A, Glycosylated/drug effects | 2 | 66.0 |
Diabetes Mellitus/blood/*diagnosis | 8 | 100.0 |
Protein Precursors/*analysis | 3 | 12.0 |
Albuminuria | 10 | 20.0 |
Diabetic Retinopathy/*epidemiology/*physiopathology | 2 | 100.0 |
Survival Analysis | 2 | 0.0 |
Creatinine/metabolism | 7 | 9.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology | 6 | 31.0 |
Diabetic Angiopathies/blood/*physiopathology | 2 | 40.0 |
Diabetic Nephropathies/blood/*physiopathology | 2 | 100.0 |
Alkaline Phosphatase/blood | 3 | 2.0 |
*Bone Density | 3 | 2.0 |
Calcium/blood | 4 | 1.0 |
Phosphorus/blood | 3 | 8.0 |
Spain/epidemiology | 2 | 1.0 |
Diabetes Mellitus, Type 2/blood/*drug therapy | 32 | 69.0 |
Sulfonylurea Compounds/*therapeutic use | 11 | 61.0 |
Biological Markers/analysis | 3 | 0.0 |
Fructosamine/*blood | 2 | 100.0 |
Mass Screening/methods | 2 | 4.0 |
Infant | 29 | 0.0 |
Valsalva Maneuver | 3 | 37.0 |
Diabetes Mellitus, Type 1/*metabolism/physiopathology | 3 | 75.0 |
Chromatography, Gel | 2 | 0.0 |
Hyperglycemia/blood | 2 | 22.0 |
Molecular Weight | 4 | 0.0 |
Linear Models | 2 | 0.0 |
Lipid Peroxidation/*physiology | 2 | 11.0 |
Lipoproteins, LDL/*blood | 3 | 1.0 |
Hypoglycemic Agents/administration & dosage | 2 | 40.0 |
Insulin/administration & dosage | 15 | 62.0 |
Diabetic Retinopathy/*physiopathology | 6 | 46.0 |
Israel | 4 | 2.0 |
Jews | 2 | 2.0 |
Puberty | 8 | 11.0 |
Socioeconomic Factors | 16 | 9.0 |
Diabetes Mellitus, Type 1/*therapy | 5 | 55.0 |
*Diet | 3 | 1.0 |
Exercise | 7 | 6.0 |
Islets of Langerhans/*metabolism | 2 | 3.0 |
Insulin/therapeutic use | 69 | 61.0 |
Social Adjustment | 2 | 20.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 4 | 1.0 |
Diabetic Nephropathies/*prevention & control | 2 | 40.0 |
Enalapril/*therapeutic use | 3 | 6.0 |
Lipids/blood/*metabolism | 2 | 11.0 |
Diabetes Mellitus, Type 2/blood/complications | 3 | 75.0 |
Diabetic Angiopathies/*etiology | 5 | 71.0 |
Diabetic Retinopathy/etiology | 2 | 40.0 |
Risk | 16 | 1.0 |
Albuminuria/*urine | 4 | 33.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Blood Pressure Monitoring, Ambulatory | 2 | 4.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology/urine | 2 | 40.0 |
Glomerular Filtration Rate/*physiology | 2 | 33.0 |
Autoantibodies/*analysis | 4 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Glycosylation | 15 | 1.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Insulin/*administration & dosage/*therapeutic use | 3 | 100.0 |
Swine | 8 | 0.0 |
Aldehyde Reductase/*antagonists & inhibitors | 2 | 13.0 |
Diabetic Neuropathies/blood | 2 | 50.0 |
Health Knowledge, Attitudes, Practice | 4 | 12.0 |
Interpersonal Relations | 5 | 21.0 |
*Adaptation, Psychological | 3 | 10.0 |
Diabetic Nephropathies/*blood | 6 | 30.0 |
Erythrocytes/*metabolism | 11 | 5.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Sodium/blood | 3 | 2.0 |
Uremia/blood | 3 | 16.0 |
Autoantibodies/blood | 5 | 2.0 |
Islets of Langerhans/immunology | 8 | 21.0 |
Membrane Glycoproteins/blood | 2 | 6.0 |
*Platelet Activation | 3 | 2.0 |
Risk Assessment | 2 | 0.0 |
Thrombospondins | 2 | 1.0 |
Combined Modality Therapy | 10 | 0.0 |
Personality Inventory | 2 | 5.0 |
Diabetes Mellitus, Type 1/*blood/drug therapy | 24 | 68.0 |
Growth Hormone/*blood | 5 | 2.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Factor Analysis, Statistical | 2 | 5.0 |
Diabetes Mellitus, Type 1/*blood/physiopathology | 8 | 42.0 |
*Obesity | 10 | 19.0 |
Blood Pressure/drug effects/physiology | 2 | 5.0 |
Diabetic Neuropathies/*drug therapy/physiopathology | 2 | 66.0 |
Diabetes Mellitus, Type 1/*blood/metabolism | 4 | 50.0 |
Hemoglobin A, Glycosylated/*metabolism | 44 | 89.0 |
Dental Plaque Index | 4 | 17.0 |
Periodontal Diseases/*etiology/pathology | 2 | 66.0 |
Periodontal Index | 6 | 12.0 |
Family Characteristics | 3 | 18.0 |
Hemoglobins/analysis | 4 | 1.0 |
Hospitalization | 5 | 4.0 |
Hypoglycemia/epidemiology | 2 | 100.0 |
*Blood Pressure | 10 | 8.0 |
Diastole | 5 | 7.0 |
*Blood Glucose Self-Monitoring | 10 | 90.0 |
Family Practice | 2 | 6.0 |
*Inpatients | 2 | 100.0 |
Autonomic Nervous System Diseases/*etiology | 2 | 66.0 |
Diabetes Mellitus, Type 2/*complications/metabolism | 2 | 50.0 |
Heart Rate/physiology | 2 | 2.0 |
DMF Index | 2 | 18.0 |
Lactobacillus/isolation & purification | 3 | 75.0 |
Streptococcus mutans/isolation & purification | 2 | 100.0 |
Diabetes Mellitus, Type 1/*complications/drug therapy/metabolism | 2 | 100.0 |
Albuminuria/etiology | 5 | 45.0 |
Kidney/*physiopathology | 5 | 8.0 |
Renal Circulation | 3 | 8.0 |
Prolactin/*blood | 2 | 0.0 |
Autonomic Nervous System/*physiopathology | 4 | 20.0 |
Autonomic Nervous System Diseases/*epidemiology | 2 | 100.0 |
Diabetic Neuropathies/*epidemiology | 4 | 100.0 |
Proportional Hazards Models | 2 | 0.0 |
Alveolar Bone Loss/complications | 2 | 100.0 |
Diabetes Mellitus, Type 2/*blood/complications/drug therapy | 2 | 66.0 |
Hypoglycemia/prevention & control | 2 | 100.0 |
Arizona/epidemiology | 3 | 25.0 |
World Health Organization | 2 | 2.0 |
Diabetes Mellitus, Type 2/*therapy | 2 | 100.0 |
Evaluation Studies | 19 | 2.0 |
*Therapy, Computer-Assisted | 4 | 57.0 |
Colony Count, Microbial | 2 | 2.0 |
Glucose/analysis | 2 | 13.0 |
Hyperglycemia/physiopathology | 2 | 40.0 |
Secretory Rate | 2 | 6.0 |
Cost-Benefit Analysis | 2 | 1.0 |
Reproducibility of Results | 7 | 0.0 |
*Self Care | 8 | 61.0 |
Lipoprotein(a)/*blood | 2 | 2.0 |
Diabetic Retinopathy | 3 | 75.0 |
Reflex | 2 | 11.0 |
Diabetic Neuropathies/*blood/physiopathology | 2 | 66.0 |
Erythrocyte Membrane/*enzymology | 2 | 6.0 |
Na(+)-K(+)-Exchanging ATPase/*blood | 2 | 10.0 |
Neural Conduction | 19 | 19.0 |
Peroneal Nerve/physiopathology | 2 | 28.0 |
Sural Nerve/physiopathology | 3 | 30.0 |
*Diabetic Diet | 13 | 59.0 |
Glucosamine/*analogs & derivatives/therapeutic use | 4 | 100.0 |
Metabolic Clearance Rate | 7 | 2.0 |
alpha-Glucosidases/*antagonists & inhibitors | 7 | 50.0 |
Body Height | 6 | 3.0 |
Carrier Proteins/*blood | 5 | 2.0 |
Diabetes Mellitus, Type 1/blood/*metabolism | 7 | 70.0 |
Growth | 3 | 6.0 |
Autoantibodies/*immunology | 2 | 0.0 |
Diabetes Mellitus, Type 1/complications/*immunology | 2 | 50.0 |
Immunoglobulin A/*blood | 2 | 7.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Preoperative Care | 2 | 1.0 |
Autoantibodies/*blood | 3 | 1.0 |
Glutamate Decarboxylase/immunology | 2 | 6.0 |
Islets of Langerhans/immunology/*secretion | 3 | 50.0 |
Alcohol Drinking | 5 | 3.0 |
Apolipoproteins/blood | 7 | 3.0 |
Peptide Fragments/*blood | 2 | 2.0 |
Circadian Rhythm | 12 | 4.0 |
Diabetes Mellitus, Type 2/*metabolism | 7 | 14.0 |
Fatty Acids, Nonesterified/blood | 13 | 6.0 |
Infusions, Intravenous | 4 | 0.0 |
Random Allocation | 35 | 7.0 |
Diabetic Nephropathies/physiopathology | 4 | 26.0 |
Diabetic Neuropathies/physiopathology | 4 | 57.0 |
Diabetic Retinopathy/physiopathology | 8 | 61.0 |
Electroencephalography | 2 | 0.0 |
*Evoked Potentials, Auditory | 2 | 6.0 |
Diabetes Mellitus, Type 1/*blood/*psychology | 3 | 100.0 |
Interviews | 3 | 7.0 |
Diabetes Mellitus, Type 1/blood/*complications/physiopathology | 4 | 100.0 |
Puberty/*blood | 3 | 17.0 |
Thyroxine/blood | 9 | 3.0 |
Electrophoresis, Agar Gel/*methods | 2 | 12.0 |
Fetal Hemoglobin/*analysis | 5 | 31.0 |
Pregnancy in Diabetics/*blood | 20 | 58.0 |
Autonomic Nervous System/physiopathology | 4 | 14.0 |
Diabetic Neuropathies/blood/*physiopathology | 5 | 55.0 |
Diabetic Angiopathies/*epidemiology | 2 | 50.0 |
Abnormalities/*epidemiology | 2 | 50.0 |
Maternal Age | 2 | 2.0 |
*Pregnancy in Diabetics | 2 | 25.0 |
Diabetic Neuropathies/*drug therapy | 3 | 60.0 |
Diabetic Nephropathies/*blood/therapy | 2 | 100.0 |
Kidney Failure, Chronic/*blood/therapy | 3 | 5.0 |
*Peritoneal Dialysis | 2 | 3.0 |
Blood Glucose | 9 | 10.0 |
Glycosuria | 10 | 58.0 |
Diabetes Mellitus, Type 1/*blood/*therapy | 2 | 100.0 |
Hospitals, University | 4 | 11.0 |
Patient Care Team | 2 | 11.0 |
Skinfold Thickness | 6 | 8.0 |
Urban Population | 2 | 1.0 |
Diabetes Mellitus, Type 2/*blood/complications | 3 | 15.0 |
Diabetic Angiopathies/blood | 4 | 28.0 |
Diabetic Retinopathy/*blood | 12 | 80.0 |
Hypertension/etiology | 3 | 6.0 |
*Albuminuria | 18 | 58.0 |
Heart Rate | 9 | 3.0 |
Albuminuria/urine | 5 | 25.0 |
Biopsy | 2 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Hydroxyproline/urine | 2 | 11.0 |
Diabetes Mellitus, Type 2/*blood/therapy | 3 | 75.0 |
*Circadian Rhythm | 5 | 2.0 |
Growth Hormone/blood | 13 | 5.0 |
Drug Stability | 3 | 1.0 |
France | 2 | 0.0 |
Quality Control | 5 | 2.0 |
Diabetes Mellitus, Type 1/blood/*drug therapy | 37 | 90.0 |
Insulin/administration & dosage/*adverse effects | 3 | 100.0 |
Patient Compliance | 23 | 15.0 |
Patient Education | 10 | 16.0 |
*Ethnic Groups | 2 | 1.0 |
Gestational Age | 8 | 0.0 |
Pregnancy/*blood | 7 | 4.0 |
Prenatal Care | 2 | 8.0 |
Great Britain | 5 | 2.0 |
Diabetes Mellitus, Type 2/blood/*metabolism | 4 | 44.0 |
Insulin/administration & dosage/blood/*pharmacology | 2 | 28.0 |
Kinetics | 16 | 0.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Lipid Peroxides/*blood | 3 | 17.0 |
Malondialdehyde/blood | 3 | 4.0 |
Drug Tolerance | 2 | 1.0 |
Food | 7 | 5.0 |
*Primary Health Care | 3 | 30.0 |
Glycerol/blood | 4 | 10.0 |
Lipoproteins, VLDL/blood | 4 | 1.0 |
Liver/*metabolism | 2 | 0.0 |
Intelligence | 4 | 12.0 |
Psychomotor Performance | 2 | 6.0 |
Diagnosis, Differential | 6 | 0.0 |
*Erythrocyte Aging | 2 | 9.0 |
*Erythrocyte Deformability | 3 | 37.0 |
Cesarean Section | 3 | 4.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology/rehabilitation | 2 | 100.0 |
*Growth | 3 | 10.0 |
Japan | 3 | 0.0 |
Weight Gain | 3 | 4.0 |
*Health Knowledge, Attitudes, Practice | 4 | 14.0 |
Diabetes Mellitus, Type 1/drug therapy/*psychology | 2 | 100.0 |
Emotions | 3 | 13.0 |
Hypoglycemia | 2 | 40.0 |
*Social Adjustment | 2 | 100.0 |
Social Support | 2 | 4.0 |
*Stress, Psychological | 2 | 13.0 |
*Patient Compliance | 10 | 22.0 |
Diabetes Mellitus/blood/*drug therapy | 5 | 71.0 |
Diabetes Mellitus, Type 1/complications/*physiopathology | 5 | 62.0 |
Glomerular Filtration Rate/physiology | 2 | 10.0 |
Acromegaly/blood/*drug therapy | 2 | 14.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Albuminuria/blood | 2 | 28.0 |
Diabetes Mellitus, Type 1/physiopathology | 3 | 27.0 |
Diabetes Mellitus, Type 2/physiopathology | 2 | 16.0 |
Hypertension/*drug therapy | 3 | 1.0 |
Neural Conduction/drug effects | 3 | 23.0 |
Temperature | 10 | 1.0 |
Vibration | 5 | 35.0 |
Diabetes Mellitus, Type 2/blood/physiopathology/*urine | 5 | 100.0 |
Eating | 14 | 10.0 |
Adenosine Diphosphate/pharmacology | 3 | 2.0 |
Administration, Oral | 14 | 1.0 |
Cholesterol Esters/blood | 3 | 2.0 |
Diabetes Mellitus, Type 2/*blood/*drug therapy | 2 | 18.0 |
Fatty Acids/*blood | 5 | 17.0 |
Linoleic Acid | 2 | 7.0 |
Linoleic Acids/blood | 2 | 22.0 |
Oleic Acid | 2 | 3.0 |
Oleic Acids/blood | 2 | 40.0 |
Phospholipids/blood | 7 | 5.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology/urine | 2 | 50.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Arizona | 2 | 6.0 |
Birth Weight | 13 | 8.0 |
Reference Standards | 3 | 1.0 |
Pirenzepine/pharmacology | 2 | 25.0 |
Pyridostigmine Bromide/pharmacology | 2 | 14.0 |
Gabon | 2 | 20.0 |
Internal Medicine | 2 | 50.0 |
Apolipoproteins A/*blood | 2 | 4.0 |
Apolipoproteins B/blood | 2 | 0.0 |
Cholesterol/*blood | 13 | 5.0 |
Diabetes Mellitus, Type 1/blood | 19 | 59.0 |
Lipoproteins, HDL Cholesterol/*blood | 4 | 1.0 |
Pregnancy Trimester, Third | 8 | 4.0 |
Proteinuria/blood | 2 | 25.0 |
Triglycerides/*blood | 10 | 2.0 |
Glucagon/blood | 10 | 10.0 |
Insulin/*secretion | 4 | 5.0 |
Epinephrine/blood | 4 | 3.0 |
Hormones/*blood | 2 | 1.0 |
Hypoglycemia/*blood | 4 | 30.0 |
Norepinephrine/blood | 4 | 2.0 |
Diabetes Mellitus, Type 1/*blood/complications | 5 | 38.0 |
Growth Hormone/*secretion | 2 | 1.0 |
Family/psychology | 2 | 33.0 |
Patient Admission | 2 | 16.0 |
Blood Bactericidal Activity | 2 | 2.0 |
Hemoglobin A/metabolism | 6 | 60.0 |
Phagocytosis | 3 | 0.0 |
Diabetes Mellitus/*blood/drug therapy | 16 | 64.0 |
Insulin Infusion Systems | 19 | 73.0 |
African Americans | 2 | 1.0 |
Hypoglycemic Agents/*administration & dosage | 3 | 27.0 |
Insulin/*administration & dosage | 25 | 73.0 |
Trisaccharides/*administration & dosage | 2 | 100.0 |
Diabetes Mellitus, Type 1/*enzymology | 4 | 36.0 |
Diabetes Mellitus, Type 2/*enzymology | 3 | 37.0 |
Electrochemistry | 2 | 2.0 |
Diabetes Mellitus, Type 2/*urine | 2 | 40.0 |
Autoantibodies/analysis | 4 | 2.0 |
Flow Cytometry | 3 | 0.0 |
Diabetic Retinopathy/complications | 3 | 50.0 |
Hemoglobin A/analysis | 26 | 72.0 |
Patient Acceptance of Health Care | 5 | 21.0 |
Periodontal Pocket/pathology | 2 | 33.0 |
Dietary Fats/administration & dosage | 3 | 3.0 |
Infusions, Parenteral | 2 | 1.0 |
Ambulatory Care | 4 | 12.0 |
Diabetes Mellitus/*blood/therapy | 8 | 80.0 |
Electrophoresis | 2 | 0.0 |
Immunoradiometric Assay | 3 | 2.0 |
Diabetic Retinopathy/diagnosis | 2 | 50.0 |
Clinical Trials | 42 | 4.0 |
Sulfonylurea Compounds/adverse effects/*therapeutic use | 3 | 100.0 |
Capillaries/pathology | 2 | 4.0 |
Glucagon/diagnostic use | 6 | 50.0 |
Niacinamide/*therapeutic use | 3 | 100.0 |
Insulin/*administration & dosage/blood/therapeutic use | 2 | 100.0 |
Insulin, Isophane/administration & dosage/therapeutic use | 2 | 100.0 |
Patient Satisfaction | 3 | 7.0 |
Bone Density/*physiology | 2 | 3.0 |
Creatinine/urine | 8 | 7.0 |
Endothelins/*blood | 3 | 11.0 |
Glipizide/*therapeutic use | 4 | 100.0 |
Lactates/blood | 4 | 5.0 |
Lactic Acid | 3 | 4.0 |
Metformin/*therapeutic use | 6 | 26.0 |
Hyperglycemia/blood/*physiopathology | 2 | 50.0 |
Posture | 2 | 2.0 |
Respiration | 4 | 7.0 |
2,3-Diphosphoglycerate | 2 | 14.0 |
Body Weight | 30 | 4.0 |
Insulin/*pharmacology | 4 | 1.0 |
Oxygen/metabolism | 2 | 0.0 |
Rats | 3 | 0.0 |
Diabetic Neuropathies/*physiopathology | 10 | 71.0 |
Diabetes Mellitus, Type 1/*immunology | 6 | 8.0 |
Fructosamine | 50 | 87.0 |
Hexosamines/blood | 19 | 82.0 |
Statistics | 5 | 1.0 |
Chromatography, Affinity | 9 | 1.0 |
Urea/blood | 3 | 9.0 |
Uremia/*blood | 6 | 18.0 |
Diabetes Mellitus, Type 1/*blood/urine | 3 | 37.0 |
*Glycoproteins | 9 | 1.0 |
Lipoproteins/*blood | 17 | 2.0 |
Occupations | 2 | 14.0 |
Diabetes Mellitus, Type 1/blood/physiopathology/*urine | 4 | 80.0 |
Diabetes Mellitus, Type 1/blood/*therapy | 6 | 85.0 |
Microcomputers | 3 | 30.0 |
Diabetes Mellitus, Type 1/metabolism/*therapy | 2 | 100.0 |
Glycosuria/urine | 4 | 80.0 |
Apolipoproteins B/analysis | 2 | 7.0 |
Hemostasis | 3 | 2.0 |
Lipids/*blood | 20 | 3.0 |
Ultracentrifugation | 2 | 1.0 |
Alpha-Globulins/*urine | 2 | 66.0 |
Diabetic Nephropathies/prevention & control | 2 | 50.0 |
Kidney Function Tests | 4 | 3.0 |
Renin/blood | 2 | 0.0 |
Insulin/blood/*secretion | 2 | 4.0 |
Mass Screening | 2 | 1.0 |
Diabetes Mellitus, Type 2/blood/*diet therapy | 5 | 71.0 |
Dietary Carbohydrates | 3 | 13.0 |
Dietary Fats | 2 | 5.0 |
Dietary Fiber | 2 | 40.0 |
Lipoprotein Lipase/blood | 3 | 3.0 |
Lipoproteins, HDL/blood | 14 | 5.0 |
Diabetes Mellitus/physiopathology | 2 | 14.0 |
Diabetic Retinopathy/complications/physiopathology | 2 | 100.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Diabetes Mellitus, Type 1/blood/*diet therapy/drug therapy | 2 | 100.0 |
*Eating | 2 | 3.0 |
*Weight Gain | 2 | 11.0 |
Exercise Test | 2 | 0.0 |
Hemodynamic Processes | 4 | 2.0 |
C-Peptide/analysis | 6 | 54.0 |
*Insulin Infusion Systems | 37 | 78.0 |
Lipids/metabolism | 2 | 0.0 |
Lipoproteins, LDL/blood | 5 | 2.0 |
Platelet Aggregation/*physiology | 2 | 8.0 |
*Kidney Transplantation | 4 | 0.0 |
*Pancreas Transplantation | 3 | 16.0 |
Diabetic Nephropathies/*physiopathology | 4 | 36.0 |
*Colorimetry | 2 | 28.0 |
*Mass Screening | 3 | 5.0 |
Thiobarbiturates/diagnostic use | 2 | 66.0 |
Diabetes Mellitus, Type 1/*blood/*physiopathology | 2 | 66.0 |
Sensory Thresholds | 4 | 25.0 |
*Electrocardiography | 3 | 5.0 |
Reflex, Pupillary | 2 | 66.0 |
*Glomerular Filtration Rate | 3 | 12.0 |
Regional Blood Flow | 2 | 1.0 |
Diabetes Mellitus, Type 2/blood | 13 | 38.0 |
Superoxides/*blood | 2 | 11.0 |
Arteriosclerosis/blood | 2 | 8.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Diabetes Mellitus/metabolism | 3 | 8.0 |
Insulin/*blood | 6 | 3.0 |
Hemoglobins/*analysis | 4 | 7.0 |
Pediatrics | 2 | 25.0 |
United States | 3 | 0.0 |
Diabetic Angiopathies/blood/*epidemiology | 2 | 100.0 |
Pennsylvania | 2 | 8.0 |
Skin/*metabolism | 2 | 1.0 |
Pregnancy in Diabetics/blood | 6 | 54.0 |
Health Status | 3 | 3.0 |
*Social Support | 3 | 27.0 |
Leukocytes/*metabolism | 2 | 2.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Magnesium/*blood | 2 | 13.0 |
Trisaccharides/*therapeutic use | 4 | 100.0 |
Retinol-Binding Proteins/*urine | 4 | 50.0 |
Coronary Disease/etiology | 3 | 8.0 |
Diabetes Mellitus/*therapy | 3 | 60.0 |
Diabetic Retinopathy/*diagnosis | 3 | 75.0 |
Injections, Intravenous | 4 | 0.0 |
Hexosamines/*blood | 28 | 90.0 |
Pregnancy in Diabetics/*blood/drug therapy | 2 | 40.0 |
Diabetes Mellitus, Type 1/*drug therapy/urine | 3 | 100.0 |
Growth Hormone/blood/*secretion | 4 | 4.0 |
Diabetes Mellitus, Type 1/blood/psychology/*rehabilitation | 3 | 100.0 |
Hyperinsulinism/blood | 2 | 18.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Patient Education/standards | 2 | 100.0 |
Hospitals, Pediatric | 2 | 40.0 |
Outpatient Clinics, Hospital | 3 | 23.0 |
Oxygen Consumption | 4 | 1.0 |
*Physical Fitness | 2 | 5.0 |
*Accidents, Traffic | 3 | 75.0 |
Diabetes Mellitus, Type 1/metabolism/*physiopathology | 5 | 83.0 |
Somatotropin-Releasing Hormone/*pharmacology | 4 | 4.0 |
Antihypertensive Agents/therapeutic use | 4 | 4.0 |
Diabetes Mellitus, Type 2/*pathology | 2 | 25.0 |
*Antiporters | 2 | 8.0 |
Insulin/analogs & derivatives/blood | 2 | 100.0 |
Monocytes/*metabolism | 2 | 0.0 |
Receptor, Insulin/*metabolism | 2 | 3.0 |
South Africa | 2 | 1.0 |
Atrial Natriuretic Factor/*blood | 2 | 3.0 |
Blood Pressure/*drug effects | 3 | 1.0 |
Diabetic Angiopathies/*physiopathology | 3 | 25.0 |
Hypertension/*physiopathology | 2 | 3.0 |
*Indians, North American | 2 | 6.0 |
Chromatography, Liquid/methods | 3 | 13.0 |
Glucose/*analysis | 2 | 33.0 |
Diabetes Mellitus, Type 1/therapy | 2 | 40.0 |
Diabetes Mellitus, Type 2/therapy | 2 | 66.0 |
Diabetes Mellitus, Type 1/blood/*drug therapy/physiopathology | 2 | 100.0 |
Insulin, Isophane/*administration & dosage/therapeutic use | 2 | 100.0 |
Diabetes Mellitus, Type 1/*metabolism/therapy | 2 | 100.0 |
Albuminuria/physiopathology | 3 | 42.0 |
Insulin/secretion | 3 | 5.0 |
Insulin Antibodies/*blood | 2 | 50.0 |
Diabetes Mellitus, Type 1/drug therapy/immunology | 2 | 100.0 |
In Vitro | 10 | 0.0 |
Diabetes Mellitus, Type 1/blood/*diet therapy | 3 | 100.0 |
Dietary Fiber/*administration & dosage | 2 | 12.0 |
Galactans/*administration & dosage | 2 | 66.0 |
Mannans/*administration & dosage | 2 | 66.0 |
*Weight Loss | 3 | 6.0 |
Asia/ethnology | 3 | 9.0 |
Research | 2 | 3.0 |
Diabetes Mellitus/*metabolism | 3 | 8.0 |
Diabetes Mellitus, Type 1/blood/genetics/*physiopathology | 2 | 66.0 |
Obesity | 10 | 16.0 |
Nigeria | 3 | 4.0 |
Proteinuria/metabolism | 2 | 14.0 |
Diabetic Neuropathies/*immunology | 2 | 100.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Autoanalysis | 2 | 7.0 |
Costs and Cost Analysis | 4 | 6.0 |
Fetal Hemoglobin/analysis | 3 | 8.0 |
Educational Status | 2 | 3.0 |
Hypoglycemia/epidemiology/etiology | 2 | 100.0 |
*Heart Rate | 4 | 8.0 |
Median Nerve/*physiopathology | 2 | 20.0 |
Neurons, Afferent/physiology | 3 | 10.0 |
Peroneal Nerve/*physiopathology | 3 | 60.0 |
Ulnar Nerve/*physiopathology | 2 | 100.0 |
Antilipemic Agents/*therapeutic use | 2 | 2.0 |
C-Peptide/blood/*secretion | 3 | 50.0 |
HLA Antigens/analysis | 4 | 1.0 |
Hong Kong | 3 | 6.0 |
*Family | 5 | 13.0 |
Kidney Failure, Chronic/*blood | 7 | 10.0 |
Lipoprotein(a) | 3 | 13.0 |
Chlorpropamide/therapeutic use | 3 | 100.0 |
Gliclazide/therapeutic use | 2 | 50.0 |
Diabetes Mellitus/blood/*psychology | 2 | 100.0 |
Problem Solving | 2 | 22.0 |
Delivery, Obstetric | 2 | 5.0 |
Community Health Services | 2 | 28.0 |
Diabetes Mellitus/*physiopathology | 5 | 25.0 |
England | 6 | 5.0 |
Diabetes Mellitus/blood/physiopathology | 3 | 42.0 |
Glyburide/*administration & dosage | 3 | 100.0 |
Spain | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood/drug therapy | 5 | 27.0 |
Diabetes Mellitus, Type 2/*blood/diet therapy/drug therapy | 2 | 100.0 |
Insulin/blood/therapeutic use | 3 | 50.0 |
False Positive Reactions | 2 | 0.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Diabetes Mellitus, Type 1/blood/nursing/*therapy | 2 | 100.0 |
Nursing Assessment/*standards | 2 | 66.0 |
Nursing Evaluation Research | 2 | 28.0 |
*Self Assessment (Psychology) | 2 | 40.0 |
Sex Hormone-Binding Globulin/*metabolism | 2 | 0.0 |
Adipose Tissue/*anatomy & histology | 3 | 5.0 |
*Body Composition | 2 | 1.0 |
Cattle | 4 | 0.0 |
Recombinant Proteins/adverse effects/therapeutic use | 2 | 6.0 |
Diabetic Ketoacidosis/etiology | 3 | 60.0 |
Hypoglycemia/etiology | 3 | 30.0 |
Recurrence | 2 | 0.0 |
Lipase/metabolism | 2 | 3.0 |
Injections, Subcutaneous/methods | 3 | 75.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Glyburide/administration & dosage/*therapeutic use | 4 | 100.0 |
Metformin/administration & dosage/*therapeutic use | 2 | 50.0 |
Diabetic Angiopathies/urine | 2 | 100.0 |
Diabetic Retinopathy/urine | 3 | 100.0 |
Hypertension/complications/urine | 2 | 100.0 |
Diabetes Mellitus, Type 1/*urine | 5 | 55.0 |
Growth Hormone/*urine | 2 | 100.0 |
Puberty/*urine | 2 | 66.0 |
Diabetes Mellitus, Type 2/blood/complications/*drug therapy | 2 | 33.0 |
Insulin/blood/*therapeutic use | 3 | 50.0 |
Blood Glucose/*physiology | 2 | 28.0 |
Electrophoresis, Agar Gel | 6 | 1.0 |
Glycosylation/drug effects | 2 | 6.0 |
Neutrophils/*physiology | 2 | 1.0 |
Staphylococcus aureus | 2 | 3.0 |
Diabetes Mellitus, Type 1/blood/*rehabilitation | 4 | 100.0 |
Diabetes Mellitus, Type 2/blood/*rehabilitation | 2 | 100.0 |
Patient Education/*methods | 5 | 50.0 |
Blood Glucose/drug effects | 2 | 10.0 |
Injections, Subcutaneous | 17 | 5.0 |
Diabetic Retinopathy/blood/*physiopathology | 3 | 75.0 |
Diabetic Retinopathy/blood/*etiology | 2 | 100.0 |
Doxazosin | 2 | 66.0 |
Protirelin/*diagnostic use | 2 | 2.0 |
Insulin, Long-Acting/therapeutic use | 2 | 100.0 |
Diabetes Mellitus/drug therapy/*physiopathology | 4 | 80.0 |
Thromboxane B2/blood | 2 | 5.0 |
Diabetes Mellitus, Type 1/drug therapy/*physiopathology | 8 | 88.0 |
Insulin/*adverse effects/therapeutic use | 2 | 100.0 |
Insulin Antibodies/analysis | 5 | 62.0 |
Electromyography | 2 | 1.0 |
Motor Neurons/*physiology | 2 | 3.0 |
Neurons, Afferent/*physiology | 2 | 7.0 |
Clinical Protocols | 2 | 3.0 |
C-Peptide/*blood/secretion | 2 | 100.0 |
Islets of Langerhans/*secretion | 2 | 18.0 |
Arteriosclerosis/*etiology | 2 | 5.0 |
Chromatography, Affinity/methods | 5 | 7.0 |
Chromatography, Ion Exchange/methods | 6 | 30.0 |
Diabetes Mellitus, Type 2/*blood/diet therapy | 2 | 50.0 |
Fatty Acids/blood | 2 | 4.0 |
Thromboxane B2/*blood | 2 | 18.0 |
Hyperlipidemia/blood/complications/*drug therapy | 2 | 25.0 |
Attitude to Health | 4 | 9.0 |
Diabetes Mellitus, Type 1/blood/*surgery | 3 | 75.0 |
Arginine/diagnostic use | 3 | 11.0 |
Pancreas Transplantation/methods/*physiology | 2 | 100.0 |
Prolactin/blood | 2 | 0.0 |
Diabetic Retinopathy/*metabolism | 2 | 8.0 |
Lysine/*analogs & derivatives/analysis | 3 | 100.0 |
*Diet, Reducing | 2 | 2.0 |
Electrocardiography | 2 | 0.0 |
Monitoring, Physiologic | 5 | 6.0 |
Diabetes Mellitus, Type 1/*psychology/therapy | 2 | 100.0 |
Patient Compliance/*psychology | 2 | 50.0 |
Hyperglycemia/*complications | 3 | 42.0 |
Propanolamines/*therapeutic use | 2 | 12.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Fetal Macrosomia/*etiology | 2 | 100.0 |
Postpartum Period | 4 | 5.0 |
Pregnancy in Diabetics/diagnosis | 2 | 100.0 |
Hemoglobin A, Glycosylated/*physiology | 2 | 100.0 |
*Neural Conduction | 6 | 30.0 |
Metformin/adverse effects/*therapeutic use | 2 | 100.0 |
Diabetes Mellitus, Type 1/blood/complications/*urine | 2 | 100.0 |
Hypertension/physiopathology | 2 | 9.0 |
Echocardiography | 2 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Diabetes Mellitus, Type 1/blood/metabolism/*psychology | 2 | 100.0 |
*Body Weight | 2 | 3.0 |
Diabetes Mellitus, Type 2/blood/complications/*physiopathology | 3 | 100.0 |
Blood Proteins/*metabolism | 5 | 2.0 |
Diabetic Nephropathies/blood/therapy | 2 | 33.0 |
*Renal Dialysis | 2 | 0.0 |
Uremia/*blood/therapy | 3 | 17.0 |
Diabetic Retinopathy/*blood/pathology | 2 | 100.0 |
Thyrotropin/blood | 7 | 1.0 |
Drug Evaluation | 4 | 1.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Diabetes Mellitus/*drug therapy/metabolism | 3 | 60.0 |
Glucose/metabolism | 8 | 3.0 |
Epinephrine/*blood | 2 | 7.0 |
Exertion | 4 | 5.0 |
Glipizide/therapeutic use | 3 | 100.0 |
Hypertension/complications/*drug therapy/physiopathology | 3 | 27.0 |
Educational Measurement | 4 | 50.0 |
*Insulin, Long-Acting | 2 | 100.0 |
Diabetes Mellitus, Type 1/blood/*psychology | 9 | 100.0 |
Diabetes Mellitus/blood/metabolism | 2 | 66.0 |
Diabetes Mellitus, Type 1/blood/*drug therapy/immunology | 2 | 100.0 |
Receptors, Interleukin-2 | 2 | 1.0 |
Diabetic Angiopathies/*drug therapy/metabolism | 2 | 100.0 |
Insulin/*adverse effects | 2 | 66.0 |
Respiratory Function Tests | 2 | 1.0 |
Apolipoproteins/*blood | 4 | 2.0 |
Nifedipine/*therapeutic use | 2 | 14.0 |
Delayed-Action Preparations | 5 | 4.0 |
Insulin/*administration & dosage/adverse effects | 2 | 66.0 |
*Fluorophotometry | 2 | 100.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Vitreous Body/*metabolism | 2 | 6.0 |
Glucose Tolerance Test/methods | 2 | 100.0 |
Islets of Langerhans/*immunology | 2 | 5.0 |
Oxygen/*blood | 2 | 4.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
History, 20th Century | 2 | 1.0 |
*Attitude to Health | 6 | 18.0 |
Depression | 2 | 18.0 |
Hypoglycemia/*chemically induced | 2 | 33.0 |
Continental Population Groups | 2 | 1.0 |
Bicarbonates/blood | 2 | 16.0 |
Saudi Arabia | 2 | 4.0 |
Diabetic Neuropathies/*diagnosis/physiopathology | 3 | 100.0 |
Reaction Time | 3 | 2.0 |
*Evoked Potentials, Visual | 3 | 10.0 |
Colorimetry | 8 | 14.0 |
Peptidyl-Dipeptidase A/*blood | 2 | 1.0 |
Thyroxine-Binding Proteins/metabolism | 2 | 14.0 |
Triiodothyronine/*blood | 3 | 10.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Diabetes Mellitus/*blood/prevention & control | 2 | 100.0 |
Apolipoproteins A/blood | 4 | 5.0 |
Catheters, Indwelling | 2 | 16.0 |
Consumer Satisfaction | 3 | 42.0 |
Diabetes Mellitus/blood/drug therapy | 2 | 28.0 |
Insulin/administration & dosage/blood/*therapeutic use | 3 | 75.0 |
Leukocyte Count | 3 | 0.0 |
Aging | 3 | 0.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Photography | 2 | 15.0 |
Outcome and Process Assessment (Health Care) | 2 | 9.0 |
Outpatient Clinics, Hospital/*organization & administration | 2 | 100.0 |
Scotland | 2 | 5.0 |
Fibrinogen/metabolism | 2 | 0.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Thrombin Time | 2 | 9.0 |
Amino Acids/analysis | 2 | 0.0 |
Carbohydrates/*metabolism | 2 | 5.0 |
Globins/genetics | 2 | 1.0 |
Diabetes Mellitus, Type 2/blood/*psychology | 2 | 100.0 |
Nephelometry and Turbidimetry | 2 | 2.0 |
Serum Albumin/*analysis | 6 | 22.0 |
Neurologic Examination | 4 | 3.0 |
*Diabetes Mellitus, Type 1 | 2 | 50.0 |
Diabetes Mellitus, Type 1/*psychology | 2 | 50.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Diabetes Mellitus, Type 1/*complications/urine | 2 | 100.0 |
Proteinuria/*etiology | 2 | 15.0 |
beta 2-Microglobulin/*urine | 3 | 21.0 |
Liver Cirrhosis/*blood | 2 | 5.0 |
Renin/*blood | 2 | 2.0 |
Diabetes Mellitus, Type 1/blood/drug therapy/*psychology | 2 | 100.0 |
*Self Concept | 3 | 17.0 |
Injections, Subcutaneous/*instrumentation | 2 | 100.0 |
Insulin/*administration & dosage/blood | 4 | 100.0 |
Hemoglobin A, Glycosylated/blood | 6 | 100.0 |
Diabetes Mellitus, Type 2/blood/*drug therapy/metabolism | 2 | 100.0 |
Immunoglobulin G/urine | 2 | 22.0 |
Hair/*analysis | 2 | 50.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Heparin/pharmacology | 2 | 0.0 |
Peripheral Nerves/*physiopathology | 6 | 66.0 |
*Cognition | 2 | 4.0 |
Insulin Infusion Systems/*adverse effects | 2 | 100.0 |
Insulin-Like Growth Factor I/*blood | 2 | 20.0 |
Somatomedins/*blood | 2 | 12.0 |
*Drug Therapy, Computer-Assisted | 2 | 66.0 |
Life Style | 2 | 1.0 |
Insulin Antibodies/*analysis | 4 | 66.0 |
Diabetes Mellitus, Type 1/*surgery | 2 | 66.0 |
Hemoglobin A/*analogs & derivatives/metabolism | 2 | 100.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Renal Dialysis | 7 | 2.0 |
Fetal Macrosomia/blood | 2 | 66.0 |
Germany, East | 2 | 28.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Hypoglycemia/chemically induced | 2 | 33.0 |
Insulin/blood/*pharmacology | 2 | 10.0 |
Diabetes Mellitus, Type 2/blood/drug therapy | 2 | 66.0 |
*Food | 2 | 2.0 |
ROC Curve | 2 | 1.0 |
Erythrocyte Volume | 2 | 10.0 |
Peripheral Nervous System Diseases/*physiopathology | 2 | 50.0 |
Synaptic Transmission | 2 | 5.0 |
Diabetes Mellitus, Type 2/blood/drug therapy/*physiopathology | 2 | 50.0 |
Regional Blood Flow/drug effects | 2 | 1.0 |
Diabetes Mellitus, Type 1/blood/*drug therapy/metabolism | 2 | 100.0 |
Lipids/*metabolism | 2 | 0.0 |
HLA Antigens/*analysis | 3 | 0.0 |
Diet | 2 | 0.0 |
Fibronectins/*blood | 3 | 11.0 |
Reagent Strips | 2 | 66.0 |
Insulin, Isophane/*therapeutic use | 2 | 100.0 |
Kidney Transplantation | 3 | 2.0 |
Hemoglobin A, Glycosylated/*blood | 2 | 100.0 |
Diabetic Retinopathy/immunology | 2 | 66.0 |
Diabetic Neuropathies/drug therapy/*physiopathology | 3 | 100.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Laboratory Techniques and Procedures | 3 | 10.0 |
Myocardial Infarction/blood | 2 | 5.0 |
Dietary Carbohydrates/administration & dosage | 4 | 14.0 |
Glycosuria/metabolism | 2 | 66.0 |
3-Hydroxybutyric Acid | 3 | 20.0 |
Hydroxybutyrates/blood | 5 | 31.0 |
Apolipoproteins B/*blood | 2 | 1.0 |
Protirelin/*pharmacology | 2 | 2.0 |
Triiodothyronine/blood | 6 | 2.0 |
Drug Combinations | 3 | 0.0 |
Glyburide/pharmacology/*therapeutic use | 2 | 100.0 |
Pyruvates/blood | 2 | 20.0 |
Diabetes Mellitus, Type 1/blood/*diagnosis | 3 | 75.0 |
Diabetes Mellitus, Type 1/*drug therapy/psychology | 2 | 100.0 |
C-Peptide/secretion | 3 | 50.0 |
Muscles/*enzymology | 2 | 2.0 |
Blood Platelets/*physiology | 2 | 1.0 |
*Chromatography, Affinity | 2 | 18.0 |
Thyroid Hormones/*blood | 5 | 8.0 |
Galactans/*therapeutic use | 4 | 100.0 |
Mannans/*therapeutic use | 4 | 100.0 |
Blood Cell Count | 2 | 0.0 |
Reticulocytes | 2 | 6.0 |
Diabetes Mellitus, Type 1/blood/diet therapy/*drug therapy | 2 | 100.0 |
Erythrocytes/*analysis | 6 | 14.0 |
Sorbitol/*blood | 2 | 66.0 |
*Platelet Aggregation | 3 | 3.0 |
Erythrocytes/analysis | 5 | 20.0 |
Skin Temperature | 2 | 5.0 |
Diabetes Mellitus, Type 1/*blood/therapy | 3 | 75.0 |
Diabetic Neuropathies/complications | 2 | 66.0 |
Lipoproteins, HDL/*blood | 7 | 3.0 |
*Blood Glucose | 3 | 27.0 |
Dietary Fiber/*therapeutic use | 2 | 25.0 |
Antithrombin III/*metabolism | 3 | 4.0 |
Liver/metabolism | 2 | 0.0 |
Obesity/blood | 2 | 5.0 |
Pregnancy in Diabetics/*drug therapy | 3 | 75.0 |
Food, Formulated | 2 | 6.0 |
Insulin/*secretion/therapeutic use | 2 | 100.0 |
Cyanates/metabolism | 2 | 100.0 |
Rheology | 3 | 4.0 |
Viscosity | 2 | 6.0 |
*Insulin Infusion Systems/adverse effects | 4 | 100.0 |
Diabetes Mellitus, Type 1/*blood/complications/drug therapy | 3 | 75.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
Self Administration | 2 | 25.0 |
*Monitoring, Physiologic | 2 | 18.0 |
Diabetic Retinopathy/*etiology | 2 | 50.0 |
Glycogen/metabolism | 2 | 4.0 |
*Exertion | 4 | 2.0 |
Monocytes/metabolism | 3 | 0.0 |
Apolipoprotein A-I | 4 | 3.0 |
Diabetes Mellitus, Type 1/drug therapy | 2 | 50.0 |
Parent-Child Relations | 2 | 20.0 |
Chromatography/methods | 4 | 14.0 |
Peritoneal Dialysis | 2 | 5.0 |
Glycosuria/diagnosis | 8 | 100.0 |
Monitoring, Physiologic/*methods | 3 | 20.0 |
Eating Disorders/*complications | 2 | 100.0 |
Specimen Handling | 3 | 3.0 |
Fetus/physiology | 3 | 6.0 |
Methods | 4 | 1.0 |
Erythrocytes/metabolism | 4 | 2.0 |
Reagent Kits, Diagnostic | 5 | 3.0 |
Diabetes Mellitus/*drug therapy | 3 | 27.0 |
Home Nursing | 2 | 100.0 |
Thiobarbiturates | 4 | 57.0 |
Pregnancy in Diabetics/*diagnosis | 2 | 100.0 |
Diabetes Mellitus, Type 1/*blood/immunology | 2 | 50.0 |
Diabetes Mellitus/blood/*metabolism | 2 | 40.0 |
*Chromatography | 3 | 37.0 |
*Electrophoresis | 2 | 25.0 |
*Electrophoresis, Agar Gel | 2 | 40.0 |
Blood Preservation | 3 | 4.0 |
Antigens/*analysis | 2 | 2.0 |
von Willebrand Factor | 3 | 10.0 |
Uric Acid/blood | 3 | 5.0 |
Beta-Globulins/*analysis | 5 | 12.0 |
beta-Thromboglobulin/*analysis | 5 | 13.0 |
Hypoglycemia/blood | 2 | 40.0 |
*Cardiac Output | 2 | 20.0 |
*Stroke Volume | 2 | 25.0 |
Technetium/diagnostic use | 2 | 7.0 |
Blood Urea Nitrogen | 2 | 3.0 |
Hemoglobin A, Glycosylated/*biosynthesis | 2 | 100.0 |
Diabetes Mellitus/blood/*therapy | 2 | 100.0 |
Homeostasis | 2 | 0.0 |
Collagen/pharmacology | 2 | 1.0 |
Insulin/*immunology | 2 | 16.0 |
Diabetes Mellitus, Type 2/drug therapy | 2 | 33.0 |
Lipoproteins, HDL Cholesterol | 9 | 19.0 |
Erythrocyte Aging | 4 | 12.0 |
Thyroxine-Binding Proteins/analysis | 3 | 21.0 |
Triiodothyronine, Reverse/blood | 3 | 10.0 |
Indicators and Reagents | 2 | 0.0 |
Chromatography | 7 | 4.0 |
*Chromatography, Ion Exchange | 2 | 66.0 |
Glycosuria/*diagnosis | 2 | 100.0 |
Lipoproteins, LDL Cholesterol | 4 | 16.0 |
Lipoproteins, VLDL Cholesterol | 2 | 15.0 |
Diabetes Mellitus/drug therapy | 2 | 18.0 |
*Pregnancy | 5 | 3.0 |
*Blood Preservation | 2 | 3.0 |
*Forensic Medicine | 2 | 4.0 |
Remission, Spontaneous | 3 | 4.0 |
Antibodies/*analysis | 2 | 1.0 |
Blood Protein Electrophoresis | 2 | 1.0 |
Hemoglobin A, Glycosylated/*analysis/biosynthesis | 2 | 100.0 |
Chromatography/*methods | 2 | 15.0 |
Microchemistry | 2 | 6.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Trypsin/blood | 2 | 40.0 |
Hemoglobin A/*analogs & derivatives/analysis | 8 | 100.0 |
Hemoglobin A/*analysis | 26 | 56.0 |
Chromatography, Ion Exchange/*methods | 4 | 44.0 |
Diabetes Mellitus/*drug therapy/immunology | 2 | 100.0 |
Insulin Antibodies/*immunology | 2 | 50.0 |
*Postpartum Period | 2 | 5.0 |
Cold | 2 | 1.0 |
Organ Size | 2 | 1.0 |
Peptides/*blood | 2 | 2.0 |
Glycosides/*analysis | 9 | 90.0 |
Hemoglobin A/*analogs & derivatives/*analysis | 3 | 100.0 |
Glycosides/analysis | 2 | 50.0 |
Blood Glucose/analysis/metabolism | 2 | 22.0 |
Glycosides/blood | 2 | 66.0 |